TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
https://doi.org/10.24060/2076-3093-2014-0-1-2-38-43
Abstract
Currently, the study of mechanisms of development and introduction of the most effective treatment for castration-resistant prostate cancer (CRPC) – one of the most highlighted problems concerning facing oncologists and urologists worldwide. Several large randomized trials recently (TAX 327 , SWOG 9916) shows high possibilities of combinations based on docetaxel. Results of different treatment schemes on the basis of docetaxel and cabazitaxel in hormone-refractory prostate cancer treatment are presented in this study. The favorable effect is received and justifies further research of efficacy of drug combination.
About the Authors
T. N. Skvortsova
City Clinical Hospital № 57, Moscow
Russian Federation
Russian Federation
S. V. Mishugin
City Clinical Hospital № 57, Moscow
Russian Federation
Russian Federation
A. A. Gritskevich
Clinical Oncology Despensary №1, Krasnodar
Russian Federation
Russian Federation
I. G. Rusakov
City Clinical Hospital № 57, Moscow
Russian Federation
Russian Federation
References
1. Алексеев Б.Я., Андрианов А.Н. Возможности и механизмы действия гормональной терапии у больных кастрационно-резистентным раком предстательной железы // Онкоурология - 2013.- №1. - С. 34-43.
2. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). - М., 2014.
3. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 году. - М., 2014.
4. Карякин О.Б. Российский опыт применения Таксотера в терапии метастатического гормонорефрактерного рака предстательной железы: результаты описательного исследования TANDEM // Онкоу- рология. - 2010. - №4. - С. 61-64.
5. Вe Bono J.S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial // Lancet. -2010. – Vol. 376 (9747) - Р. 1147-1154.
6. Berthold D.R. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study // J Clin Oncol. – 2008. – №10. - Vol. 26(2). - Р. 242-245.
7. Heidenreich A., Bolla M., Joniau S., van der Kwast T.H, Matveev VMason., M.D., Mottet N., Schmid H.-P., Wiegel T., Zattoni F.. Рекомендации по лечению рака предстательной железы. Европейская ассоциация урологов –М., 2011.
8. Kish J., Bukkapatnam R. The treatment challenge of hormone-refractory prostate cancer // Cancer Care. – 2001. - Vol. 8(6). – P. 487-495.
9. Oudard S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer // Future Oncol. – 2011. - Vol. 7 (4). – P. 497–506.
10. Petrylak DP. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer // N Engl J Med. – 2004. - №7 – Vol. 351(15). – P. 1513-1520.
11. Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann Oncol. - 2012.
12. Shigeta K., Miura Y., Naito Y., Takano T. Cabazitaxel for castration – resistant prostate cancer // Lancet. – 2011. – Vol. 377 ( 9760 ).– P. 122-123.
13. Wilkes G. Cabazitaxel, a taxane for men with hormone- refractory metastatic prostate cancer // Oncology (Williston Park) – 2010. - Vol. 24. - Suppl. 10. – P. 46-48.
Review
For citations:
Skvortsova T.N., Mishugin S.V., Gritskevich A.A., Rusakov I.G. TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER. Creative surgery and oncology. 2014;(1-2):38-43. (In Russ.) https://doi.org/10.24060/2076-3093-2014-0-1-2-38-43
Views:
587
Email this article 